Skip to main content
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. — Investor Relations & Filings

Ticker · GANX ISIN · US36269B1052 US Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2024-01-02 Capital/Financing Update
Country US United States of America
Listing US GANX

About Gain Therapeutics, Inc.

https://www.gaintherapeutics.com/

Gain Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops next-generation allosteric small molecule therapies. The company utilizes its proprietary Magellan™ drug discovery platform, which combines artificial intelligence with physics-based computational models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function to treat diseases that are currently undruggable. The company's lead candidate, GT-02287, is in Phase I clinical trials for the treatment of GBA-Parkinson’s disease. Gain's therapeutic pipeline targets neurodegenerative diseases, lysosomal storage disorders, and other conditions with high unmet medical needs.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the resale of shares and warrants by a selling stockholder. It includes detailed information about the securities offered, the plan of distribution, use of proceeds, risk factors, and corporate overview. The document is not a financial report, earnings release, or management discussion but rather a disclosure document for a securities offering. This type of filing corresponds to a capital/financing update, specifically a prospectus related to a securities offering and resale. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2024-01-02 English
Regulatory Filings 2024
Regulatory Filings
2024-01-02 English
FORM 4 SUBMISSION
Director's Dealing
2023-12-22 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting the declaration of effectiveness for a Registration Statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and specifies a timing for the effectiveness. The document is short (1009 characters) and is a formal communication related to a regulatory filing process rather than a financial report or detailed filing. It does not contain financial data, management discussion, or report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-12-22 English
Regulatory Filings 2023
Regulatory Filings
2023-12-21 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated December 19, 2023. It is a preliminary prospectus for a securities offering, describing shares of common stock and warrants to be sold by a selling stockholder. The text includes detailed information about the company, the securities being offered, risk factors, use of proceeds, plan of distribution, and legal matters. This type of filing is used for initial public offerings or other public offerings of securities and is not an annual report, earnings release, or other financial report. It is a capital markets filing related to fundraising and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-12-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.